PT - JOURNAL ARTICLE AU - Manit Saeteaw AU - Phitjira Sanguanboonyaphong AU - Jukapun Yoodee AU - Kaitlyn Craft AU - Ratree Sawangjit AU - Nuttapong Ngamphaiboon AU - Prapimporn Chattranukulchai Shantavasinkul AU - Suphat Subongkot AU - Nathorn Chaiyakunapruk TI - Efficacy and safety of pharmacological cachexia interventions: systematic review and network meta-analysis AID - 10.1136/bmjspcare-2020-002601 DP - 2021 Mar 01 TA - BMJ Supportive & Palliative Care PG - 75--85 VI - 11 IP - 1 4099 - http://spcare.bmj.com/content/11/1/75.short 4100 - http://spcare.bmj.com/content/11/1/75.full SO - BMJ Support Palliat Care2021 Mar 01; 11 AB - Aims Randomised controlled trials (RCTs) demonstrated benefits of pharmacological interventions for cachexia in improving weight and appetite. However, comparative efficacy and safety are not available. We conducted a systematic review and network meta-analysis (NMA) to evaluate the relative efficacy and safety of pharmacological interventions for cachexia.Methods PubMed, EmBase, Cochrane, and ClinicalTrials.gov were searched for RCTs until October 2019. Key outcomes were total body weight (TBW) improvement, appetite (APP) score and serious adverse events. Two reviewers independently extracted data and assessed risk of bias. NMA was performed to estimate weight gain and APP score increase at 8 weeks, presented as mean difference (MD) or standardised MD with 95% CI.Results 80 RCTs (10 579 patients) with 12 treatments were included. Majority is patients with cancer (7220). Compared with placebo, corticosteroids, high-dose megestrol acetate combination (Megace_H_Com) (≥400 mg/day), medroxyprogesterone, high-dose megestrol acetate (Megace_H) (≥400 mg/day), ghrelin mimetic and androgen analogues (Androgen) were significantly associated with MD of TBW of 6.45 (95% CI 2.45 to 10.45), 4.29 (95% CI 2.23 to 6.35), 3.18 (95% CI 0.94 to 5.41), 2.66 (95% CI 1.47 to 3.85), 1.73 (95% CI 0.27 to 3.20) and 1.50 (95% CI 0.56 to 2.44) kg. For appetite improvement, Megace_H_Com, Megace_H and Androgen significantly improved standardised APP score, compared with placebo. There is no significant difference in serious adverse events from all interventions compared with placebo.Conclusions Our findings suggest that several pharmacological interventions have potential to offer benefits in treatment of cachexia especially Megace_H and short-term use corticosteroids. Nonetheless, high-quality comparative studies to compare safety and efficacy are warranted for better management of cachexia.